On April 19, 2026, Vietnam’s Ministry of Health (MOH) issued Circular No. 12/2026, classifying smart pet collars — including those with heart rate monitoring, GPS tracking, and electrical stimulation training functions — as medical devices. This regulatory shift directly impacts exporters, importers, and technical documentation providers in the pet tech supply chain, particularly those operating between China and Vietnam.

Event Overview

On April 19, 2026, Vietnam’s Ministry of Health published Circular No. 12/2026, officially adding smart pet collars (with heart rate monitoring, GPS positioning, and electrical stimulation training capabilities) to its list of regulated medical devices. The circular mandates two requirements for importers: submission of the manufacturer’s valid ISO 13485 certification and provision of a full Vietnamese-language user manual, including explicit warnings and contraindications.

Industries Affected

Direct Exporters and Importers

Companies exporting smart pet collars from China (or other third countries) into Vietnam must now comply with medical device registration prerequisites. Previously treated as consumer electronics or general pet accessories, these products now require formal regulatory clearance — increasing lead time, documentation burden, and compliance risk.

Technical Documentation Providers

Firms specializing in regulatory translation, labeling, and manual localization face immediate demand for certified Vietnamese-language technical files. Unlike standard marketing translations, the requirement explicitly covers safety-critical content — warnings, contraindications, and usage limitations — implying stricter review standards and potential liability exposure.

Manufacturers with Integrated Quality Systems

Chinese manufacturers such as Smart Pet Devices — named in the official summary — are required to hold and submit current ISO 13485 certification. This affects firms whose quality management systems were previously aligned with ISO 9001 or product-specific standards but not designed for medical device regulatory pathways.

Key Focus Areas and Recommended Actions

Monitor MOH’s Implementation Guidance and Transitional Arrangements

Circular No. 12/2026 confirms the regulatory classification but does not specify enforcement timelines, grace periods, or grandfathering provisions for existing stock. Importers and distributors should track follow-up notices from Vietnam’s Department of Medical Equipment and Construction (DMEC) for clarity on effective dates and conformity assessment procedures.

Prioritize Documentation Localization Ahead of Certification Alignment

Translating full technical documentation into Vietnamese — including hazard statements and clinical rationale for stimulation parameters — is time-intensive and requires subject-matter expertise. Companies should initiate localization before pursuing ISO 13485 certification, as manuals may need revision to reflect medical device labeling conventions.

Distinguish Between Regulatory Signal and Operational Requirement

This circular signals Vietnam’s broader intent to regulate digitally enabled animal health tools under medical device frameworks — but it applies only to collars with specific functional combinations (e.g., physiological monitoring + stimulation). Products without both features may remain outside scope; verification against MOH’s functional definitions is essential before assuming applicability.

Engage Local Authorized Representatives Early

Vietnamese law requires foreign medical device manufacturers to appoint a local authorized representative (AR) for registration and post-market surveillance. Exporters lacking an AR in Vietnam should identify and contract one prior to submitting documentation, as the AR assumes legal responsibility for compliance.

Editorial Perspective / Industry Observation

From an industry perspective, this development is better understood as a regulatory signal than an immediate operational outcome. While the classification is formally enacted, real-world enforcement depends on DMEC capacity, inspection priorities, and market surveillance focus — none of which are yet publicly defined. Analysis来看, the inclusion of electrical stimulation alongside biometric monitoring suggests MOH is prioritizing risk-based categorization, aligning with ASEAN Medical Device Directive principles. Observation来看, Vietnam is gradually extending medical device governance beyond human-use products — a trend observed in Thailand and Malaysia, though at varying speeds and scopes. Current more appropriate interpretation is that this marks the beginning of structured oversight, not the completion of a mature regulatory pathway.

This circular underscores Vietnam’s incremental approach to regulating convergent technologies at the intersection of consumer electronics, veterinary wellness, and digital health. It does not indicate a broad ban or sudden market closure — rather, it introduces a defined compliance threshold for a narrowly specified product type. For stakeholders, the priority is not urgency alone, but precision: verifying product scope, validating documentation readiness, and confirming alignment with MOH’s functional definitions before initiating formal submissions.

Source: Vietnam Ministry of Health (MOH), Circular No. 12/2026, issued April 19, 2026.
Note: Implementation timeline, transitional provisions, and DMEC guidance documents remain pending and require ongoing observation.